Cryo-Cell International, Inc.
CCEL · NASDAQ
11/30/2024 | 11/30/2023 | 11/30/2022 | 11/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.68 | 0.01 | 0.50 | -1.05 |
| FCF Yield | 5.12% | 2.87% | -23.24% | 0.97% |
| EV / EBITDA | 58.23 | -5.29 | 7.05 | 17.92 |
| Quality | ||||
| ROIC | 1.06% | -20.89% | 6.98% | 7.67% |
| Gross Margin | 75.15% | 73.07% | 71.02% | 68.88% |
| Cash Conversion Ratio | 14.95 | -0.94 | 3.09 | 3.80 |
| Growth | ||||
| Revenue 3-Year CAGR | 1.78% | 2.76% | -0.88% | -3.17% |
| Free Cash Flow Growth | 181.64% | 114.90% | -981.69% | -87.84% |
| Safety | ||||
| Net Debt / EBITDA | 8.70 | -1.01 | 1.49 | -1.02 |
| Interest Coverage | 1.87 | -9.95 | 2.64 | 2.91 |
| Efficiency | ||||
| Inventory Turnover | 12.08 | 10.98 | 10.33 | 9.76 |
| Cash Conversion Cycle | 27.17 | -27.43 | 41.41 | 43.30 |